权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

The IL-6 Induced Retinal Iron Sequestration Response

IL-6 诱导的视网膜铁螯合反应

基本信息

批准号：
10636913
负责人：
JOSHUA L DUNAIEF
金额：
$ 40.12万
依托单位：
UNIVERSITY OF PENNSYLVANIA
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-06-01 至 2024-05-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10636913
关键词：
Aceruloplasminemia Adaptive Immune System Affect Age Age related macular degeneration Aqueous Humor Astrocytes Atrophic Autopsy Binding Bruch&apos s basal membrane structure Cell Culture Techniques Cell Surface Receptors Cell surface Cells Ceruloplasmin Choroid Chronic Complement Activation Complex Data Development Disease Down-Regulation Drusen Enzyme-Linked Immunosorbent Assay Eye Foreign Bodies Glaucoma Glial Fibrillary Acidic Protein Goals Growth Health Hereditary Disease Homeostasis Homologous Gene Host Defense Mechanism Human Hypertrophy IL-6 inhibitor IL6 gene IL6ST gene Inductively Coupled Plasma Mass Spectrometry Inflammation Inflammatory Injections Innate Immune System Interleukin 6 Receptor Interleukin-1 beta Interleukin-6 Iron Iron Overload Knock-out Knockout Mice Lead Link Lipids Macular degeneration Measures Mediating Messenger RNA Microbe Mitochondria Muller&apos s cell Mus Neural Retina Oxidative Stress Pathogenesis Pathway interactions Patients Phase I Clinical Trials Photoreceptors Play Production Proteins Regulation Retina Retinal Degeneration Retinal Diseases Retinitis Pigmentosa Role SLC11A2 gene Serum Signal Pathway Signal Transduction Specificity Stains Structure TNF gene Testing Toxic effect Transgenic Mice Up-Regulation Vascular Endothelial Growth Factors Work age related cell type cytokine early onset experimental study extracellular human tissue induced pluripotent stem cell inhibitor intravenous injection intravitreal injection membrane synthesis metal transporting protein 1 mouse model neovascularization novel novel therapeutic intervention oxidative damage prevent receptor response visual cycle

项目摘要

PROJECT SUMMARY Iron plays a critical role in both the healthy and diseased retina. The long term goals of the proposed studies are to understand how inflammation associated with retinal disease promotes iron dysregulation, and discover how to protect against retinal iron toxicity. Iron is necessary in the retina for mitochondrial energy production, membrane synthesis and the visual cycle, but becomes a central producer of oxidative stress when improperly regulated. Iron toxicity is evident in retinal disease as follows: 1) Iron causes rapid retinal degeneration following entry into the eye carried by an intraocular foreign body. 2) Human AMD retinas have more iron than age-matched controls, suggesting that iron overload may play a role in AMD pathogenesis. 3) Consistent with this hypothesis, in the inherited disease aceruloplasminemia, loss of the ferroxidase ceruloplasmin (Cp) results in retinal iron accumulation and early onset macular degeneration. 4) Mice with knockout for Cp and its homolog hephaestin (Heph) have an age-dependent retinal iron overload and degeneration sharing features of AMD, including complement activation and subretinal neovascularization (which causes wet AMD). Recent evidence from non-ocular cells indicates that interleukin 6 (IL-6) can trigger a “cellular iron sequestration response” to prevent microbes from accessing the iron they need for growth and replication. This, combined with the finding of elevated intraocular and serum IL-6 levels in AMD, suggest that IL-6 may promote retinal iron overload in AMD. Experiments proposed herein will utilize human iPSC-RPE cell culture, mouse models, and post mortem human tissue to define the IL-6 retinal iron sequestration response. An inhibitor of the IL-6 trans-signaling pathway will be tested. Following activation or inhibition of IL-6 pathways, changes in the levels of iron and its transporters will be assessed. These changes will be correlated with those in AMD versus normal post mortem retinas. It is expected that these studies will lead to development of novel anti-AMD approaches that diminish inflammation-induced iron accumulation.

项目摘要铁在健康和患病的视网膜中都起着关键作用。的长期目标拟议的研究是为了了解炎症如何与视网膜疾病相关促进铁失调，并发现如何防止视网膜铁毒性。铁是视网膜中线粒体能量产生、膜合成和细胞增殖所必需的蛋白质。视觉周期，但成为一个中央生产商的氧化应激时，调节不当。铁毒性在视网膜疾病中是明显的，如下：1）铁引起快速视网膜变性眼内异物进入眼内。2)人类AMD视网膜具有比年龄匹配的对照组更多的铁，这表明铁超载可能在AMD中起作用发病机制3)与这一假设相一致，在遗传性疾病aceroplasminemia中，铁氧化酶铜蓝蛋白（Cp）的缺失导致视网膜铁蓄积和早发性黄斑变性4)敲除Cp及其同源物Hephaestin（Heph）的小鼠年龄依赖性视网膜铁过载和退行性变共享AMD的特征，包括补体激活和视网膜下新生血管形成（导致湿性AMD）。最近来自非眼细胞的证据表明，白细胞介素6（IL-6）可以触发“细胞铁螯合反应”，以防止微生物获得他们需要的铁生长，复制的这一点，结合眼内和血清IL-6水平升高的发现，提示IL-6可能促进AMD患者视网膜铁超载。拟议的实验本文将利用人iPSC-RPE细胞培养物、小鼠模型和死后人组织以确定IL-6视网膜铁螯合反应。IL-6反式信号传导抑制剂路将被测试。在激活或抑制IL-6通路后，铁和它的运输商将进行评估。这些变化将与 AMD与正常死后视网膜。预计这些研究将导致开发新的抗AMD方法，减少炎症诱导的铁积累